KRSA vs ZYME
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KRSA · Korsana Biosciences$37.56 ▲ 5.95%
ZYME · Zymeworks$26.14 ▼ 2.68%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KRSA +260.1%
- ZYME +4.6%
Head to head
| Metric | KRSA | ZYME |
|---|---|---|
| Price | $37.56 | $26.14 |
| Change today | ▲ 5.95% | ▼ 2.68% |
| Market cap | $1.71B | $1.81B |
| Return, 3 months | +36.5% | -9.1% |
| Return, year to date | +322.5% | -0.7% |
| Return, 1 year | +262.5% | +8.8% |
| P/E (TTM) | – | 49.3 |
| P/B | 4.4 | 7.0 |
| P/E percentile vs own 5y | 51st | 100th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +828.7% |
| Net profit growth (YoY) | -113.7% | +986.1% |
| Gross margin | – | – |
| Operating margin | – | 16.6% |
| Net margin | – | 16.3% |
| Return on equity | -23.2% | 15.0% |
| Analyst target vs. price | +36.3% | +60.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 70 | 43 |
| 30-day volatility | 60.0% | 56.5% |
| Max drawdown, 1 year | -54.7% | -23.6% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ZYME is the largest of the group by market value.
- KRSA has returned the most over the past year.
- ZYME has been the calmest stock over the last 30 days.